Skip to main content
. 2017 Dec 19;19:133. doi: 10.1186/s13058-017-0918-2

Fig. 5.

Fig. 5

Circulating miR-105/miR-93-3p serves as diagnostic biomarker for TNBC patients. a Circulating miR-105 and miR-93-3p were measured in 12 normal and 118 breast cancer patient plasma samples (74 TNBC and 44 non-TNBC patients) by qPCR. b ROC curves were plotted to evaluate the predictive power of circulating miR-93-3p and miR-105 for the TNBC subtype. c A contingency plot showing the distribution of TNBC and non-TNBC patients with the indicated circulating miRNA levels. The correlation was examined by chi-square test. Mean ± SEM; * P < 0.05, *** P < 0.001, n.s. no significance. TNBC triple negative breast cancer